Immune Skin Conditions Clinical Trial

We are conducting a novel clinical trial of an immune-modulatory drug in adults with Down syndrome, funded by the National Institutes of Health INCLUDE Project.

On average, people with Down syndrome have widespread immune system dysregulation, which can impact many aspects of health. We have embarked on a multitude of studies to better understand this immune dysregulation and learn how to normalize immune function.

One of the most important studies we are performing is a clinical trial entitled "Safety and efficacy of tofacitinib for immune skin conditions in Down syndrome." 

In this study, we focus on a drug called tofacitinib to treat immune-driven skin conditions that are more common in people with Down syndrome, including alopecia aerata, atopic dermatitis, hidradenitis suppurativa, psoriasis, and vitiligo.

We will assess three main outcomes in adults with Down syndrome:

  1. The safety of tofacitinib treatment
  2. The ability of tofacitinib to treat immune-driven skin conditions
  3. The ability of tofacitinib to normalize biomarkers of immune dysregulation

In addition, in a more exploratory manner, we will begin to ask if normalizing immune function with tofacitinib can improve other autoimmune conditions that people with Down syndrome are pre-disposed to and improve cognition or overall quality of life.

Dr. Barry Martin listens with a stethoscope to a young man with Down syndrome

Curious to learn more? Expand each of the boxes below to keep reading.

You can also call us at 303-724-0491.

Linda Crnic Institute for Down Syndrome

CU Anschutz

Research Complex II

12700 East 19th Avenue

Room 4014

Aurora, CO 80045


CMS Login